These findings are the first clear proof that the CD105(+) mononuclear cells fraction in the pulmonary arterial blood of adult lung cancer patients includes mesenchymal progenitor cells.

Anti-angiogenic therapy, especially CD105-targeting, may prove an effective form of small cell lung cancer treatment.

Reaction with CD-105 antibody gave a positive result mainly in the cytoplasm of tumour cells located at the periphery of pulmonary epithelioid haemangioendothelioma.

The increased level of serum endoglin in lung cancer patients compared to controls and its changes after surgical treatment suggest potential application of soluble form of endoglin as potential tumor marker.

angiogenesis of lung cancer may be related to the interaction of SPARC, TGFbeta1 and Endoglin

DLC1 tumor suppressor regulates CD105 expression on human non-small cell lung carcinoma cells through inhibiting TGFB1 signaling.